GRFS News and Press, Grifols S.A. From 11/18/19

This article is part of a series that provides an ongoing analysis of the changes made to George Soros’s 13F stock portfolio on a quarterly basis. It is based on George Soros’s regulatory 13F Form filed on 11/14/2019. Please visit our Tracking Soros Fund Management Holdings ar...

BARCELONA, Spain , Nov. 7, 2019 /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P NASDAQ: GRFS), a leading global producer of plasma-derived medicines and a leader in the development of innovative diagnostic solutions, has now introduced AlphaID™, a new, simple cheek swab that can...

- ART enables greater workflow efficiency and lean sample management, supporting laboratories' path towards total automation - The Procleix Panther System featuring ART improves system usability, increases operator walk-away time, and allows laboratories to select efficient configurati...

This article is part of a series that provides an ongoing analysis of the changes made to George Soros’s 13F stock portfolio on a quarterly basis. It is based on George Soros’s regulatory 13F Form filed on 08/14/2019. Please visit our Tracking Soros Fund Management Holdings ar...

On August 6th, Rigel Pharmaceuticals ( RIGL ), reported their Q2 earnings and updates on their flagship product, TAVALISSE. Rigel Pharmaceuticals recorded a beat on EPS of -$0.12 by $0.02 and revenue of $10.41M, which was a beat by $1.13M. It appears that Rigel has been executing with ...

Rigel Pharmaceuticals' ( RIGL ) Tavalisse, launched in mid-2018, is experiencing sales growth but competitors exist that could potentially reduce peak sales. RIGL's partnered pipeline provides a source of potentially good news to offset any bad news regarding advances from RIGL's competitors...

The FDA has approved Grifols' (NASDAQ: GRFS ) Xembify, its new 20% subcutaneous immunoglobulin, used to treat primary immunodeficiencies. More news on: Grifols, S.A., Healthcare stocks news, Stocks on the move, Read more ...

BARCELONA, Spain , June 19, 2019 /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), one of the world's three top providers of plasma-derived medicines to treat life-threatening diseases, today announced that the VISTASEAL™ fibrin sealant will be the first product it will...

This article is part of a series that provides an ongoing analysis of the changes made to George Soros’s 13F stock portfolio on a quarterly basis. It is based on George Soros’s regulatory 13F Form filed on 05/15/2019. Please visit our Tracking Soros Fund Management Holdings ...

Rigel Pharmaceuticals (RIGL) recently reported their Q1 earnings and hosted a conference call to update investors on the TAVALISSE launch, as well as pipeline progress and the company's financials. Rigel reported $8.1M in net product sales from TAVALISSE, which was a 10% increase quarter...